AbCellera Results Presentation Deck

Q3 2022 BUSINESS UPDATE M 4 2 2 4 4 4 long live plasma cell Q3 2022. BUSINESS UPDATE SUMMARY. 10 YEARS AT THE CUTTING EDGE OF ANTIBODY DISCOVERY $868M 164 92 7 in cash, cash equivalents & marketable securities cumulative programs under contract cumulative programs started molecules in the clinic

View entire presentation